Related Experiment Video
Updated: Jun 2, 2026
In vivo Macrophage Imaging Using MR Targeted Contrast Agent for Longitudinal Evaluation of Septic Arthritis
Published on: October 20, 2013
Macrophages: a minimally invasive tool for monitoring collagen VI myopathies
Francesca Gualandi1, Rosa Curci, Patrizia Sabatelli
1Dipartimento di Medicina Sperimentale e Diagnostica, Sezione di Genetica Medica, Universitá di Ferrara, Ferrara, Italy. gdf@unife
Introduction:
Collagen VI expression was tested in peripheral blood macrophages from patients with collagen VI-related myopathies and compared with muscle biopsy.
Methods:
RNA and protein studies were performed in blood macrophages from 5 patients previously diagnosed with either Ullrich congenital muscular dystrophy (UCMD) or Bethlem myopathy (BM). The full spectrum of possible genotypes was considered, including both dominant and recessive UCMD and BM cases.
Results:
In the dominant BM patient, no collagen VI alterations were detectable in macrophages or muscle biopsy. In the remaining patients, the protein defect caused by the selected mutations, as well as the transcriptional abnormalities, were readily detectable in macrophages, at levels comparable to those observed in muscle biopsy samples and cultured skin fibroblasts.
Conclusions:
Our data support the suitability of peripheral blood macrophages as a reliable, minimally invasive tool for supplementing or replacing muscle/skin biopsies in the diagnosis and monitoring of collagen VI-related myopathies.
